Be the first to like this
Over the past few years, scientific journals and government regulators have increased the scrutiny and expectations facing pharmaceutical companies looking to publish the results of their clinical trials. While picking and choosing favorable findings may have been acceptable a decade ago, it is now considered unethical and potentially illegal. As a result of these changing expectations and regulations, global publications leaders at pharmaceutical companies are carefully building strategies that ethically present all study findings while still driving brand strength. Scientific publications are an essential tool for both clinical and commercial purposes, as they are intended to influence the target audience by raising both awareness of the disease and awareness of a company’s product. In the changing world of publications, it is vital that companies produce publications that are not only compelling, but are also in compliance with new transparency guidelines. This report, “Scientific Publications Strategy: Managing Reputation, Clinical Trial Results, and Commercial Relevance,” provides directors and managers with the research and understanding to produce effective clinical publications that possess commercial relevance.
This study identifies trends and new ways of thinking in the ways in which pharmaceutical and biotechnology companies approach global publication activities and supplies benchmarks for plan delivery outsourcing, as well as key contributors to the development of strategy and planning and the effects of the changing publications industry on journal emphasis.